Results 171 to 180 of about 11,456 (188)

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial

Circulation, 2021
Carol Pollock, Rajiv Agarwal, Aletta E. Schutte   +2 more
exaly  

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

JACC: Heart Failure, 2020
Bruce Neal
exaly  

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus

Circulation, 2018
Bruce Neal, Vlado Perkovic, Karin Rådholm   +2 more
exaly  

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

Diabetologia, 2019
Michael Hansen, Hiddo J L Heerspink, Gert Mayer   +2 more
exaly  

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Circulation, 2019
Carol Pollock, Rajiv Agarwal, Bernard Zinman   +2 more
exaly  

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial

Diabetes Care, 2013
Julio Rosenstock, Guntram Schernthaner, Gary Meininger   +2 more
exaly  

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

Diabetes Care, 2012
Julio Rosenstock, David Polidori, Keith Usiskin   +2 more
exaly  

Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes

Diabetes Care, 2015
Bruce Neal, Vlado Perkovic, Dick de Zeeuw   +2 more
exaly  

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

Metabolism: Clinical and Experimental, 2018
Lawrence A Leiter, W Timothy Garvey, James List   +2 more
exaly  

The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels

Diabetes, 2016
Gregory R Steinberg, Sarah J Mancini, Ian P Salt   +2 more
exaly